News | Radiology Imaging | February 13, 2020

AMA Issues Category lll CPT Codes for Real-time Fluorescence Wound Imaging

Reimbursement pathway established for MolecuLight’s i:X procedure in wound care

MolecuLight’s i:X procedure in wound care

February 13, 2020 — MolecuLight Inc., a leader in handheld fluorescence imaging for real-time detection of bacteria in wounds, announced that the American Medical Association (AMA) has issued two new CPT category lll codes to enable a reimbursement pathway for point-of-care real-time fluorescence wound imaging for bacterial presence, location and load using the MolecuLight i:procedureThe two new category lll codes for the MolecuLight i:X procedure are:

(1) 0598T Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (e.g. lower extremity), and

(2) 0599T each additional anatomic site (e.g. upper extremity) (List separately in addition to code for primary procedure) (Use 0599T in conjunction with 0598T)

Point-of-care fluorescence imaging of wounds is achieved using MolecuLight’s handheld fluorescence imaging device, the i:X. These Category III codes indicate no other CPT codes describe this novel procedure. The codes become active on July 1, 2020.

“The AMA’s issuance of these two new CPT codes for the MolecuLight procedure is an exciting milestone for the company and for the U.S. wound care industry overall,” said Anil Amlani, MolecuLight’s CEO. “The AMA’s diligent scrutiny of our body of clinical evidence, a foundation for granting the CPT codes, recognizes the clinical utility of a diagnostic, point-of-care device and associated procedure to detect the presence, location and load of clinically-significant bacteria. The MolecuLight i:X provides this solution and can be incorporated into all clinical care settings and wound care workflows. Through our growing global user base, we see the invaluable utility the MolecuLight procedure provides to wound care clinicians in informing and improving their wound care assessments, providing actionable information to optimize their treatments and ultimately, in improving their patient outcomes.”

“As a key participant in a number of clinical studies to validate the MolecuLight procedure, including a 350-patient study demonstrating improved wound assessment and a recent study demonstrating accelerated wound healing, I have witnessed the wide-spread utility of the MolecuLight i:X procedure,” said Windy Cole, M.D., medical director of the UH Ahuja Wound Care Center in Cleveland, Ohio. “Wound care now has a diagnostic imaging solution that provides clinicians with the real-time detection of clinically significant bacteria. This is a fundamental break-through in wound care diagnostic imaging, and we now have a reimbursement pathway to support what I believe will become the standard of care for assessment of all wounds.”

*NOTE: CPT is a registered trademark of the American Medical Association.

For more information: www.moleculight.com

Related Content

#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Getty Images

Feature | Coronavirus (COVID-19) | April 07, 2020 | By Melinda Taschetta-Millane and Dave Fornell
In an effort to keep the imaging field updated on the latest information being released on coronavirus (COVID-19), th
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2  The first of three clinical scenarios presented to the panel with final recommendations. Mild features refer to absence of significant pulmonary dysfunction or damage. Pre-test probability is based upon background prevalence of disease and may be further modified by individual’s exposure risk. The absence of resource constraints corresponds to sufficient availability of personnel, personal protective equipment, COVID-19 testing, hospital beds, and/or ve

 The first of three clinical scenarios presented to the panel with final recommendations. Mild features refer to absence of significant pulmonary dysfunction or damage. Pre-test probability is based upon background prevalence of disease and may be further modified by individual’s exposure risk. The absence of resource constraints corresponds to sufficient availability of personnel, personal protective equipment, COVID-19 testing, hospital beds, and/or ventilators with the need to rapidly triage patients. Contextual detail and considerations for imaging with CXR (chest radiography) versus CT (computed tomography) are presented in the text. (Pos=positive, Neg=negative, Mod=moderate). [Although not covered by this scenario and not shown in the figure, in the presence of significant resources constraints, there is no role for imaging of patients with mild features of COVID-19.] Image courtesy of the journal Radiology

News | Coronavirus (COVID-19) | April 07, 2020
April 7, 2020 — A multinational consens...
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 U.S. Surgeon General Jerome Adams, M.D., M.Ph demonstrates how the general public can make their own face masks for non-clinical use.

U.S. Surgeon General Jerome Adams, M.D., M.Ph. demonstrates how the general public can make their own face masks for non-clinical use.

News | Coronavirus (COVID-19) | April 04, 2020 | By Melinda Taschetta-Millane
April 4, 2020 — The Centers for Disease Control and Prevention (CDC)
Recommended best practices for nuclear imaging departments under the COVIF-19 pandemic have been issues by the ASNC and SNMMI. #COVID19 #ASNC #SNMMI #Coronavirus #SARScov2
News | Coronavirus (COVID-19) | April 03, 2020
April 3, 2020 — A new guidance document on best practices to maintain safety and minimize contamination in nuclear im
Jeannie Danker, M.D. #COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2

Jeannie Danker, M.D. Photo courtesy of The Ohio State University Wexner Medical Center

News | Coronavirus (COVID-19) | April 03, 2020 | By Melinda Taschetta-Millane
April 3, 2020 — The radiology world has lost a dedicated leader due to...
An estimated 44 million people worldwide are currently living with Alzheimer’s disease, the most common form of dementia. About 5.8 million people in the United States live with the disease, where it is the sixth leading cause of death overall. While there is not yet a cure for Alzheimer’s, researchers are working to find treatment options to delay its onset and prevent it from developing.

Image courtesy of Insightec

Feature | Ultrasound Imaging | April 02, 2020 | By Katie Caron
An estimated 44 million people worldwide are currently living with...
An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal.

An example of Philips’ TrueVue technology, which offers photo-realistic rendering and the ability to change the location of the lighting source on 3-D ultrasound images. In this example of two Amplazer transcatheter septal occluder devices in the heart, the operator demonstrating the product was able to push the lighting source behind the devices into the other chamber of the heart. This illuminated a hole that was still present that the occluders did not seal. Photo by Dave Fornell

Feature | Radiology Imaging | April 02, 2020 | By Katie Caron
A new year — and decade — offers the opportunity to reflect on the advancements and challenges of years gone by and p
#COVID19 #Coronavirus #2019nCoV #Wuhanvirus #SARScov2 Esaote won a tender launched by Consip on behalf of Civil Protection for the distribution of diagnostic equipment in Italy to face COVID-19 emergency.

Esaote won a tender launched by Consip on behalf of Civil Protection for the distribution of diagnostic equipment in Italy to face COVID-19 emergency.

News | Ultrasound Imaging | April 02, 2020
April 2, 2020 — Esaote, an Italian company among the world leader